Dr. Reddy's Laboratories Limited · RDY · Next earnings

Dr. Reddy's Laboratories Limited reports Friday, Oct 23, 2026

RDY reports before market open with consensus EPS at $0.09 and revenue at $892.2M. Last quarter: Dr. Reddy’s: Mix-led margin gains and semaglutide rollout

Reports Before market open0 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $0.09 Calendar consensus
Consensus revenue $892.2M Calendar consensus
Report date Oct 23, 2026 Friday, date estimated
Session Before market open 0 days away

Where RDY left off: FY2027 Q2

Full report

Dr. Reddy’s: Mix-led margin gains and semaglutide rollout

EPS surprise — Reported — vs $0.09
Revenue surprise — Reported — vs $892.2M
Stock move -0.3% Event window
Subsequent drift 0.0% Up to 20 sessions

Maintained overall guidance; management lowered FY27 capex guidance and continues to target higher profitability.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Raw-material inflation and geopolitical supply-chain disruption could pressure EBITDA.
  • Semaglutide validation and abatacept approval timelines remain execution points.
  • Competition in biosimilars and generics could weigh on growth.
  • PSAI weakness and mixed European performance remain concerns.

Questions analysts left open

  • Whether gross-margin gains are sustainable as mix changes.
  • Semaglutide validation and launch sequencing.
  • Rising SG&A versus productivity savings.
  • Future R&D spending after this quarter’s reduction.
  • Europe and PSAI performance.

Ask FN2 about RDY next report

Transcript, numbers and history already loaded
What should I watch for in RDY's next earnings report?How did RDY guide last quarter, and is consensus above or below that?Give me the bull and bear case going into RDY earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the RDY recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent RDY quarters

All RDY earnings
-0.3%FY2027 Q2-9.4%FY2027 Q1-0.7%FY2026 Q4

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2027 Q2

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.